Most Favored Patient Act of 2026

On March 5, 2026, Rep. Meuser (R-PA) introduced HR7837, the Most Favored Patient Act of 2026. The bill amends the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing. The bill has been referred to the Committees on Energy and Commerce and Ways and Means. As an introduced bill in early stages, it has no scheduled markup or vote, but its existence establishes a policy marker for future drug pricing reform. The bill's mechanism is direct: it would require manufacturers to provide access to the most-favored-nation price (the lowest price offered in any other country) to Medicare beneficiaries. The model would run for five years starting January 1, 2029. This is authorization legislation — it does not appropriate funds, but it mandates a pricing model that would reduce government spending on drugs without requiring new appropriations. The CBO would likely score this as deficit-reducing. The structural impact is clear: US pharmaceutical companies derive the majority of their profits from the US market, where prices are 2-4x higher than in comparable OECD countries. Linking Medicare prices to the lowest global price would directly compress the highest-margin revenue segment for companies like Pfizer ($PFE), Merck ($MRK), Eli Lilly ($LLY), and AbbVie ($ABBV). These companies have the largest Medicare Part B and Part D drug portfolios. Companies with lower US exposure or primarily non-Medicare revenue (such as pure-play biosimilar makers or OTC-heavy companies) would be less affected. Real market data shows that the pharmaceutical sector has already been under pressure. Over the 30 days ending April 30, 2026, Merck ($MRK) has declined 7.84%, Pfizer ($PFE) has declined 5.27%, and Johnson & Johnson ($JNJ) has declined 6.15%. Eli Lilly ($LLY) is down 0.83% over 30 days but saw a volatile week ending with a 3.18% gain to $912.10. AbbVie ($ABBV) ended the same week up 6.17% at $210.98. These mixed moves suggest the market is not fully pricing in the most-favored-nation threat yet, possibly due to the early legislative stage. The legislative timeline is long. For this bill to become law, it must pass both the House and Senate and be signed by the President. The bill is currently in the earliest stage: referred to committee. No hearings, markups, or companion Senate bills exist. This will not become law in 2026. The key legislative milestones to watch are: referral to subcommittee, CBO scoring, hearings, and any inclusion in broader health or budget reconciliation bills. Its sponsor, Rep. Meuser, is a relatively junior House member (first elected 2018), not a committee chair, which limits immediate momentum. However, drug pricing remains a bipartisan pain point, and the most-favored-nation concept has been proposed by both parties in different forms.